Are there patent applications covering the “heparin biosynthetic pathway”?
Yes. Patent filings can cover either (1) engineered ways to biosynthesize heparin (or heparin-like glycosaminoglycans) from precursor molecules, or (2) step-specific enzymes, genetically engineered cells, and process conditions used to assemble the heparin/heparan-sulfate–type structures. The exact scope depends on the specific application (assignee, claims, and cited prior art), and “heparin biosynthetic pathway” is often described more precisely in patents as heparin/heparan sulfate biosynthesis, enzymatic pathways, or synthetic biology routes.
What do these patent applications usually claim?
Across heparin-biosynthesis–type filings, claims commonly target at least one of the following:
- Pathway enzymes (or enzyme variants) that catalyze steps in heparan sulfate/heparin-like glycosaminoglycan modification.
- Engineered cells or recombinant expression systems that produce the desired heparin/heparan sulfate structures.
- Methods of producing the product, including substrate choices, expression/production conditions, and downstream processing.
- Compositions defined by structural features (for example, specific sulfation patterns or molecular weight distributions), even if the patent text uses “heparin-like” language.
Because patents are claim-driven, two applications can both mention heparin biosynthesis but differ sharply in what they protect (a specific enzyme vs. a full end-to-end production method vs. a particular product structure).
How can you find the specific “heparin biosynthetic pathway” application you mean?
To identify the right application, you usually need one or more of the following search anchors:
- Applicant/assignee name (company or university)
- Inventor names
- A specific process term from the patent (for example, an enzyme name or pathway step)
- Product wording used in claims (heparin, heparan sulfate, heparin-like, sulfation pattern, etc.)
- Patent publication number (WO/EP/US) or priority year
If you share any of those details, I can help narrow to the likely application(s) and summarize how the claims map to the biosynthetic pathway.
Is DrugPatentWatch useful for heparin-biosynthesis patents?
DrugPatentWatch mainly tracks patents related to drugs and drug products (approvals, exclusivity, and related patent status). It can be useful if your question is really about a heparin-related therapeutic product’s patent landscape rather than a pure “biosynthetic pathway” method patent. You can search it directly here: https://www.drugpatentwatch.com/
Quick clarification that affects the search
When you say “heparin biosynthetic pathway patent application,” do you mean:
1) a patent application for producing heparin by biosynthesis (process/enzyme/cell engineering), or
2) a patent application about heparin as a drug (formulation, manufacturing, or therapeutic use), or
3) something narrower like “heparin biosynthesis” in the biology sense (enzymes in humans/animals)?
Reply with the country/publication type (WO/US/EP/etc.), an assignee name, or any enzyme/keyword you’ve seen, and I’ll help pinpoint the relevant patent application and what it claims.